Breast Cancer Trials

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Aron Goldhirsch, W. C. Wood, Alan S. Coates et al. · Annals of Oncology · 2011 · 3.8K citations · Full text

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

Breast Oncology, Long-term Effects, Medicine +7

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Alan S. Coates, Eric P. Winer, Aron Goldhirsch et al. · Annals of Oncology · 2015 · 1.8K citations · Full text

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

Viviana Galimberti, Bernard F. Cole, Stefano Zurrida et al. · The Lancet Oncology · 2013 · 1.2K citations · Full text

Ibcsg 23–01, Surgical Pathology, Sentinel-node Micrometastases +5

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 905 citations

Tamoxifen Treatment, Clinical Effectiveness, Medicine +8